Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Health Catalyst's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Health Catalyst's regulatory disclosures and financial reporting.
Health Catalyst, Inc. Chief Financial Officer Jason Alger disposed of 26,970 shares of common stock at an average price of $1.6599 per share. The shares were sold automatically to cover tax withholding on vested restricted stock units under the company’s equity plans, not as a discretionary trade. After this tax-withholding sale, he holds 741,644 shares directly.
Health Catalyst, Inc. CEO Albert Benjamin reported a Form 4 transaction involving common stock. On March 2, 2026, he disposed of 4,966 shares of common stock at $1.6599 per share as a tax-withholding disposition related to vesting of restricted stock units. This sale was mandated under the company’s equity incentive plan as a “sell to cover” transaction and was not a discretionary trade. Following this transaction, he directly owned 1,528,433 shares of common stock.
Larson-Green Julie reported acquisition or exercise transactions in this Form 4 filing.
Health Catalyst, Inc. director Julie Larson-Green received an equity award of 8,361 restricted stock units (RSUs) of common stock. The RSUs were granted under the company’s 2019 Stock Option and Incentive Plan and each RSU represents a right to one common share. Under the Non-Employee Director Compensation Policy, 100% of these RSUs vested on March 1, 2026. Following this grant, she directly owns 81,934 shares of Health Catalyst common stock.
Health Catalyst, Inc. Chief People Officer Linda Llewelyn reported a tax-related share disposition. On March 2, 2026, 13,836 shares of common stock were disposed of at $1.6599 per share to cover tax withholding tied to restricted stock unit vesting. After this mandated “sell to cover” transaction under the company’s equity incentive plans, she held 329,651 shares directly. The footnote clarifies this was not a discretionary trade.
Health Catalyst, Inc. reported a Form 144 for restricted common stock sales by an individual associated with compensation shares. The filing lists 26,970 restricted shares proposed to be sold on 03/02/2026 through Morgan Stanley Smith Barney LLC on Nasdaq. The filing also discloses prior sales in the past three months: 20,619 shares sold on 12/01/2025 and 7,522 shares sold on 02/26/2026, both identified as restricted stock transactions by Jason Alger.
Benjamin Albert submitted a Form 144 reporting an intended sale of restricted common stock of Health Catalyst, Inc. on 03/02/2026. The filing lists 4,966 shares in connection with broker Morgan Stanley Smith Barney LLC and shows a prior sale of 13,304 shares on 02/26/2026.
Health Catalyst, Inc. (restricted shares reported for sale)
The filing reports a proposed resale of 25,795 restricted shares to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026. The filing also documents prior restricted-share dispositions by Daniel Burton: 55,715 shares on 12/01/2025 and 28,875 shares on 02/26/2026. Shares outstanding were 70,730,884 as of 03/02/2026.
Health Catalyst, Inc. filed a Form 144 reporting 13,836 common shares to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026, listed as restricted stock issued for compensation. The filing shows earlier dispositions by Linda Llewelyn of 9,762 shares on 12/01/2025 and 4,471 shares on 02/26/2026 with aggregate amounts of $28,311.75 and $7,814.41 respectively. Shares outstanding were reported as 70,730,884 as of 03/02/2026.
Health Catalyst, Inc. filed a Form 144 registering 20,838 shares of common stock for sale on 03/02/2026.
The filing identifies the broker Morgan Stanley Smith Barney LLC and lists the securities as restricted stock issued as compensation. The excerpt also reports prior restricted‑stock sales by Benjamin Landry of 14,387 shares on 12/01/2025, 27,425 shares on 12/05/2025, and 6,317 shares on 02/26/2026.
Health Catalyst, Inc. reported a Form 144 notice for the proposed sale of 15,726 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026.
The filing also discloses recent insider sales by Kevin Freeman: 16,401 shares sold on 12/01/2025 for $47,566.18 and 6,614 shares sold on 02/26/2026 for $11,559.95.